Abstract
Impact of First-Line Use of Caplacizumab on Treatment Outcomes in Immune Thrombotic Thrombocytopenic Purpura: News From the REACT-2020 Cohort
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have